**Supplemental Table 2. The** **Newcastle-Ottawa Scale (NOS) for assessing the quality of including studies**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Studies**  First Author |  | **Selection** | | |  | **Comparability** | | |  | **Assessment of outcome** | | |  | **Total Quality Score** |
| Representativeness of CCB Use Arm(s) | Selection  of the non-CCB Use Arm(s) | Origin of Exposure Source | Demonstration that Outcome of Interest was not Present at Start of Study | Studies Controlling the Most Important Factors | Studies Controlling the Other Main Factors | Assessment of Outcome with Independency | Adequacy of Follow-up Length (to assess outcome) | Lost to Follow-up Acceptable (less than 10% and reported) |
| Wiewel 2017 (18) |  | \* | \* | \* |  | \* | \* | \* |  | \* | \* | \* |  | 9 |
| Lee 2017 (19) |  | \* | \* | \* |  | \* | \* | \* |  | \* | \* |  |  | 8 |
| Kim 2019 (20) |  | \* | \* | \* |  | \* | \* | \* |  | \* | \* |  |  | 8 |
| Hsieh 2020 (21) |  | \* | \* | \* |  | \* | \* | \* |  | \* | \* |  |  | 8 |
| Roquetaillade 2020 (22) |  | \* | \* | \* |  | \* | \* | \* |  | \* | \* |  |  | 8 |

Abbreviations: CCB calcium channel blockers.